A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Completed · Phase 1/Phase 2

Conditions studied: Advanced Cancer

In brief

The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.

Key facts

Study ID

NCT03098550

Run by

Bristol-Myers Squibb

People needed

105

Starts

2017-06-15

Expected to finish

2020-07-06

Last updated by the study team

2021-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
• Patients with metastatic or advanced solid tumors
• Women with histologically or cytologically confirmed triple negative breast carcinoma
• Participants with histologically or cytologically confirmed pancreatic adenocarcinoma
• Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)

You may not qualify if…

• Active brain metastases or leptomeningeal metastases.
• Any serious or uncontrolled medical disorder
• Prior malignancy active within the previous 3 years
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Pacific Shores Medical Group — Long Beach, California, United States
• University Of Colorado — Aurora, Colorado, United States
• Moffitt Cancer Center — Tampa, Florida, United States
• University Of Michigan — Ann Arbor, Michigan, United States
• Providence Portland Medical Center — Portland, Oregon, United States
• Local Institution — St Leonards, New South Wales, Australia
• Local Institution — Edmonton, Canada
• Local Institution — Lyon, France
• Local Institution — Marseille, France
• Centre Paul Strauss — Strasbourg, France
• Universitaetsklinikum Carl Gustav Carus — Dresden, Germany
• Medizinische Universitaetsklinik Freiburg — Freiburg im Breisgau, Germany
• Universitaetsklinik Heidelberg — Heidelberg, Germany
• Local Institution — Milan, Italy
• Istituto Nazionale Tumori Fondazione Pascale — Naples, Italy
• Fundacion De Investigacion — San Juan, Puerto Rico
• Hospital Gral. Univ. Gregorio Maranon — Madrid, Spain
• Local Institution — Majadahonda - Madrid, Spain
• Klinik Fur Onkologie — Basel, Switzerland
• University Hospital of Lausanne — Lausanne, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.